SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is currently a hot topic, facing intense debate as a significant portion of the community labels it a "scam" and "rugpull," expressing frustration with its founder and predicting further declines. In contrast, a vocal bullish segment sees current levels as an ideal accumulation opportunity, anticipating a "parabolic bullrun" and "legendary bounce" as sentiment appears to hit despair. This polarized discussion reflects broader market anxieties, with some investors suggesting a shift of capital towards AI stocks.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is trending as its Cocky Wings LLC food truck franchise generates real-world revenue, leading to token buybacks and driving strong community engagement. The "flock" is highly bullish on this scalable Real World Asset (RWA) model, actively discussing passive earning opportunities through locking $COCK in the Arena. This Cardano-based token stands out for its unique utility and collective optimism for continued growth.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

Midnight Crypto ($NIGHT) is seeing increased discussion driven by its recent "Glacier Drop" airdrop, major exchange listings, and a significant surge in trading volume. The community is actively debating its potential as a leading privacy-focused blockchain within the Cardano ecosystem, often comparing its innovative approach to regulatory-compliant privacy with other projects.

Colliers International Group, Inc. engages in the provision of commercial real estate services to corporate and institutional clients. It offers outsourcing and advisory services, lease brokerage, and sales brokerage. It operates through the following segments: Real Estate Services, Engineering, Investment Management, and Corporate. The Real Estate Services segment relates to Americas, EMEA, and Asia Pacific regions. The Engineering segment refers to engineering and project management. The Investment Management segment is involved in a global alternative asset manager with long-standing, cycle tested expertise. The Corporate segment includes the costs of global administrative functions and corporate head office. The company was founded on July 31, 1988, and is headquartered in Toronto, Canada.

Colliers International Group Inc

Colliers International Group is trending as it accelerates its strategic expansion into AI-powered innovation through a Google Cloud partnership, alongside significant acquisitions boosting its engineering and investment banking capabilities globally. The community is keenly observing how CIGI's aggressive diversification into high-value, recurring service lines will deliver growth, with many emphasizing that disciplined execution of these complex initiatives is key for investor confidence. This strategic positioning in critical growth areas highlights CIGI's push to lead in the evolving commercial real estate landscape.

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics Inc

Protagonist Therapeutics is trending due to significant community speculation regarding a potential acquisition by Johnson & Johnson, fueled by their existing partnership and strong clinical data. Investors are actively discussing the impressive efficacy of rusfertide in polycythemia vera and icotrokinra in inflammatory conditions, which is also driving increased trading volume and numerous analyst upgrades. This strong pipeline progress, combined with M&A buzz, positions PTGX as a notable biotech to watch.

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. It operates through the following segments: Healthcare and Non-Healthcare. The Healthcare segment develops, manufactures, and markets a variety of noninvasive monitoring technologies and hospital automation solutions and therapeutics. The Non-Healthcare segment designs, develops, manufactures, markets and sells a broad portfolio of premium, high-performance audio products and services. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Masimo Corp

Masimo is currently trending due to a federal jury's ruling ordering Apple to pay for patent infringement related to blood-oxygen monitoring, alongside the reinstatement of an import ban on certain Apple Watch models. The community is actively discussing potential outcomes, including licensing deals or an acquisition, while also noting Masimo's recent strong earnings and strategic divestiture of its consumer audio business to sharpen its focus on healthcare innovation. Many investors are observing oversold technical indicators, anticipating a potential rebound as these developments unfold.

Molina Healthcare, Inc. engages in the provision of health care services. It operates through the following segments: Medicaid, Medicare, Marketplace, and Other. The company was founded by C. David Molina in 1980 and is headquartered in Long Beach, CA.

Molina Healthcare Inc

Molina Healthcare is trending after significantly lowering its annual profit forecast, citing unexpectedly high medical and administrative costs, especially within its ACA Marketplace business. This has caused a sharp stock decline, leading to mixed community sentiment. While many investors are bearish, others view the current valuation as an oversold opportunity, frequently referencing broader discussions around potential ACA subsidy extensions across the healthcare sector.

Euronav NV is a Belgian independent tanker company engaged in the ocean transportation and storage of crude oil. The company is based in Antwerp, Belgium. and has a global presence of subsidiaries in several regions. The company was founded in 1989. Alexander Saverys has been the CEO of the company since 2023.

CMB.Tech NV

CMBT is trending following its merger with Golden Ocean Group, establishing it as the largest global dry bulk operator. The community views the combined entity as significantly undervalued, anticipating robust future earnings and potential dividend increases driven by strong Capesize and VLCC rates within the shipping sector. This optimism fuels discussions of substantial upside potential for the post-merger company.

Ethereum Classic

Ethereum Classic ($ETC) is trending amidst intense community debate, with many users expressing frustration over its lagging performance compared to other major cryptocurrencies. Despite widespread sentiment of being "stuck" at current levels and experiencing "fake pumps," a vocal segment of the community maintains long-term bullish conviction, actively accumulating and anticipating a significant breakout. Discussions frequently revolve around its historical cycles, perceived market manipulation, and the expectation for ETC to eventually reflect broader crypto market rallies.

EHang Holdings Ltd. engages in the provision of aerial vehicle technology platform company. It also provides unmanned aerial vehicle (UAV) systems and solutions: air mobility (including human transportation and logistics), smart city management, and aerial media solutions. The firm operates through the following geographical segments: P.R.C., West Asia, East Asia, South America, Europe, and Other. The company was founded by Huazhi Hu and Yifang Derrick Xiong in December 2014 and is headquartered in Guangzhou, China.

EHang Holdings Ltd - ADR

EHang Holdings

EHang is actively trending due to mixed sentiment following a revenue guidance cut that has disappointed some investors and fueled skepticism about its near-term financial trajectory. However, the company continues to generate significant discussion around its progress in obtaining regulatory approvals for pilotless eVTOLs, launching new long-range models like the VT35, and expanding commercial trials across global markets, leading many to view it as a leader in urban air mobility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Raymond James reiterated $COGT at a Strong Buy rating, $30 price target and said, remain Strong Buy rated on $COGT shares and highlight herein some additional commentary following our Strategy Series chat with CEO Andy Robbins last week. 
 
With three important bezuclastinib 4Q25 catalysts on tap (pivotal PEAK P3 data in GIST, pivotal APEX P2 data in AdvSM and bezu&#39;s NonAdvSM NDA filing), this name has been the subject of meaningful inbound investor interest. 
 
On that note, we reviewed the set-up into PEAK (notably the pre-specified number of progression events have not yet been reached), and APEX, as well as commercial planning for the anticipated NonAdvSM 3Q/4Q26 approval/launch. 
 
Bottom line, we continue to view bezuclastinib as a best-in-class agent in systemic mastocytosis and continue to like the chances for a positive PEAK readout in GIST, unlocking a $1.5B revenue opportunity that we currently do not model. 
 
$BPMC - $SNY

Pogi

Snoopy Dawgin

Guggenheim⬆️the PT on $COGT to $20 from $17 and reiterated at a Buy. 
$PFE $NVS 
BMPC - $SNY $CLDX DCPH - OPHLY SNDX  
Guggenheim said in its note:

StockTwits Web

Cogent Biosciences Inc

Pfizer Inc

Novartis AG

Sanofi-Aventis

Celldex Therapeutics Inc.

Quantumup

Stifel⬆️ $COGT to Buy/$40 from Hold/$16 
$PFE $GSK $OPHLY 
Stifel said in its note: 
Today, COGT reported overwhelmingly positive results in the Ph3 PEAK study of bezuclastinib plus sunitinib vs. sunitinib alone in 2L GIST patients. 
 
Upgrading to Buy rating and raising TP to $40.  
 
The combination arm PFS of 16.5 months is significantly higher than investor expectations (11-12 months) and our &gt;13 month bar to get more constructive. 
 
This result also helps ward off competitive pressure from IDRX/GSK, which at CTOS reported a Ph1 PFS of 15 months in 2L GIST (see here). 
 
We update our model to reflect broad utilization of the combination in GIST (~$1.1B global peak sales for 2L GIST), give additional ex-US credit, and to reflect M&amp;A premium in our TP. We now value COGT at ~4x EV/5yr forward sales, which is in line with recent biotech M&amp;A of (~4-5x deal value/5yr forward sales).

Blueprint Medicines Corp

 at a Strong Buy rating, $30 price target and said, remain Strong Buy rated on 

 shares and highlight herein some additional commentary following our Strategy Series chat with CEO Andy Robbins last week. 
 
With three important bezuclastinib 4Q25 catalysts on tap (pivotal PEAK P3 data in GIST, pivotal APEX P2 data in AdvSM and bezu's NonAdvSM NDA filing), this name has been the subject of meaningful inbound investor interest. 
 
On that note, we reviewed the set-up into PEAK (notably the pre-specified number of progression events have not yet been reached), and APEX, as well as commercial planning for the anticipated NonAdvSM 3Q/4Q26 approval/launch. 
 
Bottom line, we continue to view bezuclastinib as a best-in-class agent in systemic mastocytosis and continue to like the chances for a positive PEAK readout in GIST, unlocking a $1.5B revenue opportunity that we currently do not model. 
 
